Sun Pharma Advanced Research Co (NSE:SPARC) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)


NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
67 GF Score
Price ₹239.37
GF Value ₹4,497.64
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co LT-Debt-to-Total-Asset?

Sun Pharma Advanced Research Co NSE:SPARC +0.02% 67 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates NSE:SPARC with a GF Score™ of 67/100 and a GF Value™ of ₹4,497.64 (Possible Value Trap). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sun Pharma Advanced Research Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Sun Pharma Advanced Research Co's long-term debt to total assets ratio declined from Mar. 2025 (0.32) to Mar. 2026 (0.00). It may suggest that Sun Pharma Advanced Research Co is progressively becoming less dependent on debt to grow their business.

Sun Pharma Advanced Research Co  (NSE:SPARC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sun Pharma Advanced Research Co LT-Debt-to-Total-Asset Related Terms

Sun Pharma Advanced Research Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co LT-Debt-to-Total-Asset Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.02 0.02 0.32 0.00

Sun Pharma Advanced Research Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.00 0.32 0.00 0.00
NSE:SPARC
67GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharma Advanced Research Co LT-Debt-to-Total-Asset Calculation

Sun Pharma Advanced Research Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=16.6/21708.6
=0.00

Sun Pharma Advanced Research Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=16.6/21708.6
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Sun Pharma Advanced Research Co (NSE:SPARC) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sun Pharma Advanced Research Co and its competitors.
Is Sun Pharma Advanced Research Co's LT-Debt-to-Total-Asset too high?
Sun Pharma Advanced Research Co's current LT-Debt-to-Total-Asset is 0.00. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Sun Pharma Advanced Research Co's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sun Pharma Advanced Research Co and its competitors. Sun Pharma Advanced Research Co's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,497.64, compared to a current price of ₹239.37 — trading 94.7% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Sun Pharma Advanced Research Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued. The current stock price of ₹239.37 is trading 94.7% below its estimated GF Value™ of ₹4,497.64. GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.

Key valuation signals for NSE:SPARC:

  • LT-Debt-to-Total-Asset: 0.00
  • GF Value™: ₹4,497.64 vs. price of ₹239.37 (94.7% below fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
67GF Score

Get the complete analysis for NSE:SPARC

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹239.37
Price
₹4,497.64
GF Value